TOKYO, Japan, 4th July 2022 – EPS International Holdings Co., Ltd. (“EPS International” hereafter) and EPS Corporation (“EPS” hereafter), both of which are wholly owned subsidiaries of EPS Holdings, Inc., announced that EPS International and EPS have decided to merge through an absorption-type merger, with EPS as the surviving company and EPS International as the absorbed company on 1st September 2022.

1. Purpose of the Reorganization

Last year, the EPS Group celebrated its 30th anniversary and conducted a management buyout (MBO), moving toward "The New EPS". The reorganization of the domestic CRO business was completed on schedule as of 1st July 2022, and this reorganization is related to the overseas business following the domestic business.
EPS International has been expanding its services to overseas clients, especially inbound projects from Europe, the U.S., and China, focusing not only on functional services, in which some development functions are outsourced in Japan, but also on full services requiring an in-country clinical trial manager. Recently, however, the business environment surrounding CROs has been undergoing significant changes.
As years go by, Multi-National Clinical Trials are becoming the mainstream of clinical trials, and the use of real-world data, including patient registry data, is being expanded. Cross-border data sharing is expected to be further accelerated in the future as globalization progresses and the barriers between clinical trials and the real world are becoming lower.
The purpose of this reorganization is to provide solutions that meet the needs of a New Era in both domestic and overseas operations by integrating the experience, project management and know-how of EPS, a leading company in the CRO industry that provides drug development support services in Japan, and EPS International, which focuses on full-service drug development support for overseas clients.
The EPS Group will contribute to the further progress of the health industry by providing high-quality services as a good partner to its customers, as well as strengthening the local medical system and improving people's health.

2. Scheduled Merging Effective Date

1st September 2022

3. Overview of Reorganization

*As of 1st July 2022

[About EPS group]
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions from development to marketing, sales, consultation covering Asia centered in China and new values created in big data & AI, regenerative medicine, etc. The strength of EPS Group lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services.

[Contact]
Corporate Communications Office
EPS Holdings, Inc.
Email: